Technology Crops International (TCI), Winston-Salem, NC, was issued a letter of no objection from the U.S. Food and Drug Administration for TCI’s self-affirmed GRAS filing of Buglossoides arvensis oil (trade name: Ahiflower oil). This proprietary omega-rich dietary oil contains the highest levels of non-GM omega-3 essential fatty acids among commercially available dietary plant oils, combining ALA (alpha linolenic acid) and a uniquely high level of SDA (stearidonic acid). Ahiflower also contains significant levels of GLA (gamma linolenic acid), an omega-6 essential fatty acid, and oleic acid, an omega-9 fatty acid.
Ahiflower is a more efficient omega-3 alternative to flax, chia, and other ALA-rich dietary oils because the SDA content of Ahiflower oil metabolizes to EPA (eicosapentaenoic acid) as much as 3 times more effectively than equivalent amounts of ALA. EPA is commonly sourced from fish oils. Results from a recently-concluded double-blind placebo-controlled human clinical trial, which compares Ahiflower oil utilization to that of flax, will be published early in 2015.